At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 569 enrolled
Drug / intervention
Nivolumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)
In Brief
A Phase 3 clinical trial evaluating Nivolumab, Topotecan, and 1 other intervention for Lung Cancer. Completed, enrolled 569 participants across 151 sites in 25 countries.
Detailed Summary
The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesAustralia, Austria, Belgium, Brazil, Chile, China, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Norway, Poland, Romania, Russia, South Korea, Spain, Switzerland, Taiwan, United Kingdom, United States
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartSep 2015
Primary CompletionAug 2018
Study CompletionAug 2022
TodayJul 2026
First PostedJun 25, 2015
Enrollment StartSep 14, 2015
Primary CompletionAug 17, 2018
Study CompletionAug 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 11.0 years ago
Interventions
Nivolumabdrug
Topotecandrug
Amrubicindrug